FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer

J Clin Oncol. 2005 May 20;23(15):3311-3. doi: 10.1200/JCO.2005.11.691.
No abstract available

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / mortality
  • Colonic Neoplasms / pathology*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Approval
  • Female
  • Fluorouracil / therapeutic use*
  • Humans
  • Leucovorin / therapeutic use*
  • Male
  • Maximum Tolerated Dose
  • Neoplasm Invasiveness / pathology*
  • Neoplasm Staging
  • Organoplatinum Compounds / therapeutic use*
  • Oxaliplatin
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Survival Analysis
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration

Substances

  • Organoplatinum Compounds
  • Oxaliplatin
  • Leucovorin
  • Fluorouracil

Supplementary concepts

  • Folfox protocol